RxDoctor Payments Data

Maggie Knight

Psychiatric/Mental Health · Spanish Fort, ALNPI 1689255598

Payments from drug & device makers

$1,137in general payments, 2019–2025

Across 30 payments — averaging $37.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$272
  • Teva Pharmaceuticals USA, Inc.$223
  • Bard Peripheral Vascular, Inc.$179
  • Alkermes, Inc.$141
  • Johnson & Johnson$127
  • Supernus Pharmaceuticals, Inc.$125
  • plus $71 from 2 others

What the payments were for

  • Food & beverage$1,09096%
  • Education$474%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,137 in reported general payments places this provider in the 50th percentile of 378 psychiatric/mental health providers in Alabama.

See all psychiatric/mental health providers in Alabama

Medicare billing

Part B allowed, 2024
$19,248
Medicare patients
42
Services billed
308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine24$325,385
Austedo XrDeutetrabenazine15$108,760
Invega SustennaPaliperidone Palmitate20$59,231
AristadaAripiprazole Lauroxil15$39,721
Aripiprazole69$16,060
TrintellixVortioxetine Hydrobromide12$11,192
Paliperidone ErPaliperidone12$3,918
Duloxetine Hcl73$3,196
Quetiapine Fumarate122$2,894
Buspirone Hcl122$2,401
Desvenlafaxine Succinate ErDesvenlafaxine Succinate34$2,381
Doxepin Hcl53$2,289
Trazodone Hcl151$1,569
Bupropion XlBupropion Hcl31$1,347
Paroxetine Hcl53$1,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$223$434,14539 claims
Johnson & JohnsonInvega Sustenna$127$59,23120 claims
Alkermes, Inc.Aristada$141$39,72115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 378 psychiatric/mental health providers in Alabama.

Other psychiatric/mental health in Spanish Fort

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →